TP53 and breast cancer: MDA-MB-231 breast cancer cells treated with Compound 4.27 after etoposide pre-treatment exhibited increased p53 acetylation, consistent with Compound 4.27 exhibiting on-target cellular inhibition of Sirt1 [147].